Vlado Perkovic's Publications

• WCN24-1001 EFFECT OF CORTICOSTEROIDS ON KIDNEY AND SAFETY OUTCOMES IN IGA NEPHROPATHY ACROSS DIFFERENT LEVELS OF PROTEINURIA AND EGFR: A POST HOC ANALYSIS OF THE TESTING STUDY

  Journal articles

  2024

  Kidney International Reports

• WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL

  Journal articles

  2024

  Kidney International Reports

• Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression

  Journal articles

  2023

  Journal of the American Society of Nephrology

• Effect of SGLT2 Inhibitors on Discontinuation of Reninangiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

  Journal articles

  2023

  Journal of the American Society of Nephrology

• The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial

  Journal articles

  2023

  Diabetes, Obesity and Metabolism

• Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide

  Journal articles

  2023

  European Heart Journal

• Abstract 17437: Estimated Lifetime Benefits of Combination Therapy With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-Steroidal MRAs in Patients With Type 2 Diabetes and Albuminuria

  Journal articles

  2023

  Circulation

• Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials

  Journal articles

  2023

  Diabetes, Obesity and Metabolism

• The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

  Journal articles

  2023

  Nephrology Dialysis Transplantation

• Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial

  Journal articles

  2023

  Circulation

• The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials

  Journal articles

  2023

  Diabetes, Obesity and Metabolism

• Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials

  Journal articles

  2023

  Diabetes, Obesity and Metabolism

• Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials

  Journal articles

  2023

  Nephrology Dialysis Transplantation

• Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

  Journal articles

  2023

  Journal of the American Heart Association

• A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

  Journal articles

  2023

  Nature Medicine

• Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials

  Journal articles

  2023

  Kidney International

• Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial

  Journal articles

  2023

  Diabetes, Obesity and Metabolism

• Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

  Journal articles

  2023

  American Journal of Kidney Diseases

• 3807 HEART FAILURE IN ASCEND-ND AND ASCEND-D

  Journal articles

  2023

  Nephrology Dialysis Transplantation

• 4333 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY

  Journal articles

  2023

  Nephrology Dialysis Transplantation

• Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering

  Journal articles

  2023

  BMJ Open Diabetes Research and Care

• Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial

  Journal articles

  2023

  Clinical journal of the American Society of Nephrology : CJASN

• Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis

  Journal articles

  2023

  Nephrology Dialysis Transplantation

• Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

  Journal articles

  2023

  The Lancet

• IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

  Journal articles

  2023

  Kidney International Reports

• Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

  Journal articles

  2023

  Kidney International Reports